KEGG   DRUG: Antithrombin alfaHelp
Entry
D08858                      Drug                                   

Name
Antithrombin alfa (INN/USAN);
Atryn (TN)
Product
Formula
C2191H3451N583O656S18
Exact mass
49001.9576
Mol weight
49032.5271
Sequence
HGSPVDICTA KPRDIPMNPM CIYRSPEKKA TEDEGSEQKI PEATNRRVWE LSKANSRFAT
TFYQHLADSK NDNDNIFLSP LSISTAFAMT KLGACNDTLQ QLMEVFKFDT ISEKTSDQIH
FFFAKLNCRL YRKANKSSKL VSANRLFGDK SLTFNETYQD ISELVYGAKL QPLDFKENAE
QSRAAINKWV SNKTEGRITD VIPSEAINEL TVLVLVNTIY FKGLWKSKFS PENTRKELFY
KADGESCSAS MMYQEGKFRY RRVAEGTQVL ELPFKGDDIT MVLILPKPEK SLAKVEKELT
PEVLQEWLDE LEEMMLVVHM PRFRIEDGFS LKEQLQDMGL VDLFSPEKSK LPGIVAEGRD
DLYVSDAFHK AFLEVNEEGS EAAASTAVVI AGRSLNPNRV TFKANRPFLV FIREVPLNTI
IFMGRVANPC VK
(Disulfide bridge: 8-128, 21-95, 247-430; Glycosylation site: 95, 135, 155, 192)
  Type
Peptide
Class
Cardiovascular agent
 DG01662  Factor Xa inhibitor
 DG01950  Antithrombotic agent
  DG01662  Factor Xa inhibitor
Remark
Product: D08858<US>
Efficacy
Anticoagulant, Factor Xa inhibitor
  Disease
Hereditary antithrombin deficiency [DS:H01381]
Comment
Antithrombin binds to thrombin and makes thrombin inactivetad.
recombinant human antithrombin [HSA:462] [KO:K03911]
Prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. It is not for treatment of thromboembolic events in hereditary antithrombin deficient patients.
Target
F10 [HSA:2159] [KO:K01314]
Interaction
Drug interaction
Brite
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Serine peptidases
    F10
     D08858  Antithrombin alfa (INN/USAN) <US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D08858
BRITE hierarchy
Other DBs
CAS: 84720-88-7
PubChem: 96025541
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system